Cardlytics Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardlytics stock.
View analyst ratings for Cardlytics or view top-rated stocks.

Wall Street analysts have given Cardlytics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardlytics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cardlytics.

Cardlytics, Inc. (NASDAQ:CDLX) posted its earnings results on Tuesday, May, 4th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.22. The firm earned $53 million during the quarter, compared to analysts' expectations of $51.96 million. Cardlytics had a negative net margin of 34.32% and a negative trailing twelve-month return on equity of 20.85%. The business's revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.26) EPS.
View Cardlytics' earnings history.

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX stock has increased by 142.1% and is now trading at $110.94.
View which stocks have been most impacted by COVID-19.

Cardlytics issued an update on its second quarter 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $58 million-$65 million, compared to the consensus revenue estimate of $57.41 million.

6 brokers have issued 1 year price targets for Cardlytics' shares. Their forecasts range from $75.00 to $160.00. On average, they expect Cardlytics' stock price to reach $132.17 in the next twelve months. This suggests a possible upside of 19.1% from the stock's current price.
View analysts' price targets for Cardlytics or view top-rated stocks among Wall Street analysts.

63 employees have rated Cardlytics CEO Scott Grimes on Glassdoor.com. Scott Grimes has an approval rating of 86% among Cardlytics' employees.

Some companies that are related to Cardlytics include GDS (GDS), FactSet Research Systems (FDS), Weibo (WB), Dada Nexus (DADA), Chindata Group (CD), TripAdvisor (TRIP), DoubleVerify (DV), Switch (SWCH), Medallia (MDLA), DigitalOcean (DOCN), OneConnect Financial Technology (OCFT), Sabre (SABR), Rackspace Technology (RXT), Magnite (MGNI) and HUYA (HUYA).
View all of CDLX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), The Walt Disney (DIS), Alibaba Group (BABA), The Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.55%), JPMorgan Chase & Co. (5.68%), Morgan Stanley (3.15%), Lord Abbett & CO. LLC (2.70%), Ameriprise Financial Inc. (1.69%) and Geode Capital Management LLC (1.54%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Great Lakes Advisors LLC, Ameriprise Financial Inc., JS Capital Management LLC, Bank of New York Mellon Corp, Allianz Asset Management GmbH, Great West Life Assurance Co. Can, and Russell Investments Group Ltd.. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, and Scott D Grimes.
View insider buying and selling activity for Cardlytics or view top insider-selling stocks.

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Principal Financial Group Inc., Principal Financial Group Inc., TimesSquare Capital Management LLC, and Geode Capital Management LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics or or view top insider-buying stocks.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDLX stock can currently be purchased for approximately $110.94.

Cardlytics has a market capitalization of $3.65 billion and generates $186.89 million in revenue each year. The company earns $-55,420,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

Cardlytics employs 578 workers across the globe.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics is headquartered at 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected]